-+ 0.00%
-+ 0.00%
-+ 0.00%

Bluejay Diagnostics says SYMON-II pivotal study completes enrollment of 750 patients for Symphony IL-6 test

PUBT·08/13/2026 10:04:56
Listen to the news
Bluejay Diagnostics says SYMON-II pivotal study completes enrollment of 750 patients for Symphony IL-6 test
  • Bluejay Diagnostics reported Q2 2026 progress on its SYMON-II pivotal study for the investigational Symphony IL-6 test.
  • Targeted enrollment of 750 hospital patients is complete; results have not been presented in the release.
  • Work continues on validation intended to support a planned FDA 510(k) submission, a key step toward commercialization.
  • Manufacturing readiness moved forward with a U.S. manufacturing contract aimed at reducing supply-chain risk.
  • Cash totaled $9.6 million at June 30, 2026; management expects funding to last through Q2 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bluejay Diagnostics Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.